24 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
DecisionAid #Orals #DM2 ... #Diabetes #Endocrinology ... #Pharmacology #
Stages in the Development of Diabetes Type 1

#Diabetes #Type1 #TypeI #DM1 #Stages #Development #Pathophysiology #Timeline #Diagnosis
#Type1 #TypeI #DM1 ... #Development #Pathophysiology ... Timeline #Diagnosis #Endocrinology
Drugs for Heart Failure

#medications #chf #pathophysiology #cardiology #pharmacology
#medications #chf ... #pathophysiology ... #cardiology #pharmacology
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - Pharmacology ... Sulfonylureas #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... mL/minute/1.73 m2 ... #Metformin #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
Diabetes Combination Tablets - Estimated A1c Lowering 
Metformin + DPP4 
• Janumet (metformin + sitagliptin) 
•
Tablets #Oral #DM2 ... #Pharmacology # ... Pills #Endocrinology
Pathophysiology of Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar Syndrome (HHS)
Absolute Insulin deficit:
 - Type I DM:
Pathophysiology ... deficit: - Type I DM ... produced - Type II DM ... #dka #hhs #pathophysiology ... #comparison #endocrinology
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
SGLT2 Inhibitors - Pharmacology ... mL/minute/1.73 m2 ... SGLT2 #Inhibitors #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
Iron Deficiency in Congestive Heart Failure (CHF)

Iron deficiency (ID) in heart failure is a common comorbidity
Heart Failure (CHF ... Heart #Failure #CHF ... #pharmacology # ... pathophysiology ... #cardiology
Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
development of HF ... resynchronization therapy; DM ... medical therapy; HF ... #CHF #Congestive ... Algorithm #Management #Cardiology